Lisavanbulin clinical trials
Also written BAL101553.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How each study uses lisavanbulin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- BAL101553
- 4
Studies by the year they started
4 studies that test it; most in 2011 (1)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of Antimitotic agents source
- One of Immune checkpoint inhibitors source
Studies
Open first, then newest update. How each study uses lisavanbulin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade GliomaCompletedPhase 1/2Basilea PharmaceuticaNCT02490800Written as Lisavanbulin Phase 1 dose escalation portion
- Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed GlioblastomaTerminatedPhase 1Basilea PharmaceuticaNCT03250299Written as Microtubule-Targeted Agent BAL101553
- An Open-Label Study of Intravenous BAL101553 in Adult Patients With Solid TumorsCompletedPhase 1/2Basilea PharmaceuticaNCT01397929Written as BAL101553
- Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent GlioblastomaCompletedPhase 1/2Basilea PharmaceuticaNCT02895360Written as BAL101553
Codes
What other systems call lisavanbulin · ClinicalTrials.gg INT000271
- MeSH (NLM) C000599741lisavanbulinOne source ClinicalTrials.gov
- UNII (FDA) 5PT0QP06X5LISAVANBULINConfirmed FDA, Wikidata
- Wikidata Q27262705lisavanbulinConfirmed FDA, Wikidata
- NCI Thesaurus C97664LisavanbulinOne source FDA
- DrugBank DB15224One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000599741 | lisavanbulin | One source ClinicalTrials.gov |
| UNII (FDA) | 5PT0QP06X5 | LISAVANBULIN | Confirmed FDA, Wikidata |
| Wikidata | Q27262705 | lisavanbulin | Confirmed FDA, Wikidata |
| NCI Thesaurus | C97664 | Lisavanbulin | One source FDA |
| DrugBank | DB15224 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.